

**Annual General Meeting of Shareholders
of
HLS THERAPEUTICS INC.
(the “Company”)**

**June 7, 2024
REPORT OF VOTING RESULTS**

Pursuant to Section 11.3 of
National Instrument 51-102 – *Continuous Disclosure Obligations* (“NI 51-102”)

In accordance with section 11.3 of NI 51-102 and following the annual general meeting of shareholders of the Company held on June 7, 2024 (the “Meeting”), we hereby advise of the following voting results as tabulated.

Total common shares issued and outstanding at record date (May 3, 2023)	31,814,547
Total shares represented at the Meeting in person and by proxy	21,098,254
Percentage of total shares represented at the Meeting	66.32%

Election of Directors

The election of directors was conducted by ballot. Each of the ten nominees in the Company’s management information circular dated May 8, 2024 was elected to serve until the end of the next annual meeting of shareholders or until his or her successor is duly elected or appointed. The percentage of votes cast “for” or “withheld” from the vote are set forth below opposite the name of each elected director based on proxies and votes received at the Meeting.

Name of Nominee	Votes Cast FOR	% of Vote Cast FOR	Votes WITHHELD	% of Votes WITHHELD
John Welborn	18,209,962	88.85	2,284,420	11.15
Craig Millian	19,959,739	97.39	534,643	2.61
John Hanna	19,135,935	93.37	1,358,447	6.63
Rodney Hill	19,959,554	97.39	534,828	2.61
Laura Brege	19,118,129	93.28	1,376,253	6.72
Norma Beauchamp	16,442,226	80.23	4,052,156	19.77
Kyle Dempsey	19,032,703	92.87	1,461,679	7.13
Christian Roy	19,135,933	93.37	1,358,449	6.63

Re-Appointment of Auditor

An ordinary resolution to re-appoint Ernst & Young LLP to serve as the independent auditor of the Company and authorizing the directors of the Company to fix the auditor’s remuneration was approved by ballot. Based on proxies and votes received at the Meeting, 21,098,117 votes (100%) were cast “for” and 137 votes (0%) were withheld.